Indivior

Suboxone SL Tabs

Indivior is a global pharmaceutical company specializing in the treatment of opioid dependence. Founded as a spin-off from Reckitt Benckiser in December 2014, Indivior has played a pivotal role in advancing opioid addiction treatment options. The company's mission is to offer medicines and treatments that can transform the lives of individuals battling addiction and its related conditions.

History[edit | edit source]

Indivior was established following the decision by Reckitt Benckiser to demerge its pharmaceutical division, allowing for a more focused approach on addiction treatment. Since its inception, Indivior has been at the forefront of developing and marketing products designed to treat opioid dependence, a critical issue affecting millions worldwide.

Products[edit | edit source]

The flagship product of Indivior is Suboxone (buprenorphine and naloxone), a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid dependence. Suboxone works by reducing withdrawal symptoms and cravings, which are significant barriers to overcoming opioid addiction. The company has also developed other products and formulations to address various aspects of opioid dependence and its treatment.

Research and Development[edit | edit source]

Indivior invests heavily in research and development (R&D) to innovate and improve treatment options for opioid dependence. The company's R&D efforts are focused on understanding the science of addiction and developing new therapies that can offer better outcomes for patients. Indivior's commitment to research has led to the development of new formulations and delivery systems for its medications, making treatment more accessible and effective.

Controversies[edit | edit source]

Indivior has faced legal challenges and controversies, particularly related to its marketing practices and the patent protection of Suboxone. The company has been accused of engaging in anti-competitive practices to extend the patent life of Suboxone, thereby delaying the entry of generic versions into the market. These legal issues have led to significant financial settlements and have raised questions about the pharmaceutical industry's role in addressing the opioid crisis.

Corporate Social Responsibility[edit | edit source]

Indivior places a strong emphasis on corporate social responsibility (CSR), with initiatives aimed at reducing the stigma of addiction, supporting communities affected by opioid dependence, and promoting responsible prescribing practices. The company's CSR efforts are designed to complement its business objectives while making a positive impact on society.

Future Directions[edit | edit source]

Looking forward, Indivior is focused on expanding its product portfolio and exploring new treatment areas beyond opioid dependence. The company aims to leverage its expertise in addiction treatment to address other challenges in the field of mental health and substance abuse. With ongoing research and development, Indivior seeks to introduce innovative therapies that can improve patient outcomes and quality of life.